ADXS News and Press, Advaxis From 10/19/22

Ayala Pharmaceuticals ( NASDAQ: AYLA ) and Advaxis ( OTCQX:ADXS ) are merging in an all stock transaction to focus on the development of cancer therapies. Under the agreement, each outstanding common share of Ayala will be converted into the right to receive com...

Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders w...

Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders w...

Advaxis press release ( OTCQX:ADXS ): Q3 GAAP EPS of -$3.83. As of July 31, 2022, the company had ~$28.2M in cash and cash equivalents. For further details see: Advaxis GAAP EPS of -$3.83

Announced completion of first dose level and enrollment initiation for second dose level in investigator-sponsored study of ADXS-504 in biochemically recurrent prostate cancer Cash runway extends into fiscal third quarter of 2024 MONMOUTH JUNCTION, N.J., Sept. 12, 2022 (GL...

Evaluation completed of first dose level in investigator-sponsored study in biochemically recurrent prostate cancer Enrollment initiated for second dose level MONMOUTH JUNCTION, N.J., June 29, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnol...

Announced Publication of ADXS-PSA Data in The Oncologist Presented Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting Presented study design of Phase 1 investiga...

Advaxis (OTC:ADXS -13.8%) to implement a one-for-80 reverse split of its issued and outstanding common stock . The reverse stock split will become effective as of 12:00am ET on June 6, 2022, and the company’s common stock is expected to begin trading on a split-adjusted basis when...

MONMOUTH JUNCTION, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it has filed a Certificate of Amendme...

Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients with prior disease progression on KEYTRUDA ® ( pembrolizumab) Updated data continue to show disease control ra...